Transce3nd’s West Pharmaceutical WST Stock Holding History

Transce3nd’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2	Closed	-$657	–	1608
2024 Q4	$657	Buy	+2	New	+$629	﹤0.01%	1275

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Transce3nd's WST Position: Q1 2025 in Review

Transce3nd sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 2 shares — an estimated $657 sold.

Transce3nd first reported a position in WST in Q4 2024 and held it in 1 quarter. The position peaked at $657 in Q4 2024. 713 funds tracked by Wall St. Rank hold WST as of Q1 2025.

Transce3nd reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 2 West Pharmaceutical shares in Q1 2025, an estimated $657.
Transce3nd first reported a position in West Pharmaceutical in Q4 2024 and held it in 1 quarter.
Transce3nd's West Pharmaceutical position peaked at $657 in Q4 2024.
713 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.